Stockreport

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

TScan Therapeutics, Inc.  (TCRX) 
PDF Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of e [Read more]